相关临床试验
544
42 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
22
4.0%
已完成
346
63.6%
Enrolling By Invitation
2
0.4%
No Longer Available
2
0.4%
尚未招募
18
3.3%
招募中
58
10.7%
暂停
3
0.6%
终止
68
12.5%
Unknown
3
0.6%
撤回
22
4.0%
暂无批准数据
- Researchers at Gladstone Institutes discovered that CD8 T cells specific for SARS-CoV-2, Epstein-Barr virus, and cytomegalovirus share enhanced cytolytic features in long COVID patients, published in Cell Reports Medicine. - The study used combinatorial tetramer technology and CyTOF to analyze virus-specific CD8 T cells in their near-native state from a "pristine" cohort of patients infected only once before vaccine availability. - Enhanced cytolytic activity was especially pronounced in women with long COVID, reinforcing the importance of sex-specific differences in the condition. - The most profound immune changes were found in cytomegalovirus-specific CD8 T cells rather than SARS-CoV-2-specific cells, adding evidence that herpesviruses may play key roles in long COVID.
- A Phase 1 clinical trial has begun testing a novel cancer vaccine that uses the Mirasol process to inactivate cancer cells while preserving their immune-stimulating properties. - The trial involves eight patients with recurrent ovarian cancer who will receive personalized vaccines created from their own tumor cells treated with UV light and riboflavin. - The approach aims to preserve neoantigens that conventional treatments destroy, potentially offering a more effective way to stimulate immune responses against cancer. - Expert opinions are divided, with some supporting the whole-cell approach while others cite the historical failure of similar strategies.
- Enterome's OncoMimics™ immunotherapy EO2463 achieved a 100% objective response rate (6/6 patients) when combined with rituximab in previously untreated follicular lymphoma patients, with 5 complete responses and 1 partial response. - The SIDNEY Phase 2 trial also demonstrated a 52.6% objective response rate with EO2463 monotherapy in follicular lymphoma patients in the watch-and-wait setting, offering an alternative to standard watchful waiting. - EO2463 represents a novel off-the-shelf immunotherapy that targets multiple B-cell markers (CD20, CD22, CD37, CD268) through bacteria-derived peptides that mimic tumor antigens and expand memory T-cells. - Enterome plans to initiate Phase 3 testing of EO2463 in watch-and-wait patients in 2026, addressing an unmet medical need in follicular lymphoma treatment.
- Researchers at Sylvester Comprehensive Cancer Center developed a novel protocol using TL1A-Ig fusion protein and low-dose IL-2 to expand regulatory T cells before stem cell transplant, demonstrating improved survival rates and reduced GVHD severity in preclinical studies. - The therapy works by stimulating the patient's own immune system to create a safer transplant environment while maintaining graft-versus-leukemia activity, offering an alternative to broad immune suppression. - Preclinical results showed higher survival rates, better tissue integrity, and a more diverse gut microbiome, with the protocol working entirely in vivo to expand Tregs in key organs like the colon, liver, and eyes. - The approach could simplify treatment and make stem cell transplants more accessible by eliminating the need to manipulate donor cells outside the body, with clinical trials being planned.
- Analysis of over 10,000 cancer trials from 2008-2024 shows federally funded studies comprise only 16.9% of trials but focus on underserved areas like rare cancers and pediatric populations. - Government-funded trials are more likely to involve complex multimodality treatments, dose de-escalation studies, and early-phase research that industry typically avoids. - Federal funding proves essential for rural and high cancer mortality counties, with over 25% of counties with trials having only federally sponsored studies. - Researchers emphasize sustained federal investment is critical to maintain a balanced cancer research ecosystem serving all patient populations.
- UCLA and UC Davis will co-lead the PRISM Trial, a $16 million randomized controlled study evaluating artificial intelligence support for mammogram interpretation across seven academic medical centers. - The study represents the first large-scale randomized trial of AI in breast cancer screening in the United States, involving hundreds of thousands of mammograms across California, Florida, Massachusetts, Washington, and Wisconsin. - Researchers aim to determine whether AI tools help radiologists detect more cancers or simply increase false positives, addressing a critical evidence gap as AI-assisted mammograms become increasingly common in clinical practice. - The patient-centered trial will maintain routine screening procedures while randomly assigning mammograms to be interpreted either by radiologists alone or with FDA-cleared AI assistance from Transpara by ScreenPoint Medical.
- A groundbreaking study published in Nature reveals that naturally occurring autoantibodies can dramatically influence cancer immunotherapy effectiveness, with some boosting patient response rates by five to ten-fold. - Researchers analyzed over 6,000 types of autoantibodies in 374 cancer patients receiving checkpoint inhibitors using the novel REAP technology platform. - Autoantibodies targeting interferons were linked to better anti-tumor responses, while others hindered treatment effectiveness, offering new targets for combination therapies. - The findings provide crucial insights into why checkpoint inhibitors work for some patients but not others, potentially extending benefits to more cancer patients.
- Stanford Medicine researchers have developed a revolutionary blood test that analyzes cell-free RNA molecules to detect cancers at various stages, including early-stage lung cancer with 73% accuracy. - The test can monitor cancer treatment resistance that doesn't involve genetic mutations, potentially allowing earlier intervention before disease progression becomes apparent on scans or through symptoms. - The novel method focuses on analyzing approximately 5,000 rare abundance genes not typically expressed in healthy blood, increasing cancer detection capability by over 50-fold. - Beyond cancer applications, the test shows promise for monitoring tissue injury in non-cancerous conditions, including acute respiratory distress syndrome and COVID-19 severity assessment.
- The Lupus Research Alliance has launched its Targeted Research Program on Engineered Cell Therapies for Lupus (TRP-ECT), awarding grants to 11 researchers developing innovative cellular treatments. - Funded projects include faster CAR T cell production methods, selective targeting of harmful B cells while sparing protective ones, and novel approaches using regulatory T cells and natural killer cells. - The initiative builds on promising clinical results where CD19 CAR T cell therapy induced complete remission in lupus patients who had failed previous treatments, potentially offering a path to drug-free disease management.
- Fred Hutch researchers have identified KEAP1 gene inactivation as a critical mechanism behind chemotherapy resistance in small cell lung cancer, offering new insights into why initially effective treatments fail. - Using patient-derived xenograft mouse models, scientists demonstrated that KEAP1 loss creates both chemoresistance and a therapeutic vulnerability through altered glutamine metabolism that could potentially be targeted with new drugs. - Clinical data analysis confirmed KEAP1 mutations in 6% of SCLC patients, with these mutations correlating to worse treatment responses and overall survival, validating the real-world relevance of the laboratory findings.
